Starting this September, the NHS will expand its respiratory syncytial virus (RSV) vaccination program to include all adults aged 65 to 74 who are clinically identified as being at increased risk. This expansion targets individuals with chronic respiratory conditions or weakened immune systems, broadening the reach of a campaign that previously prioritized older age groups and pregnant women to protect against severe winter illness, according to official NHS England guidance.
The RSV vaccine is a critical component of the national strategy to alleviate pressure on the healthcare system during the winter months. RSV is a common respiratory virus that, while typically causing mild, cold-like symptoms, can lead to serious lung infections such as pneumonia and bronchiolitis in older adults and infants. By vaccinating those at higher risk, the NHS aims to reduce hospital admissions and the overall incidence of severe complications during the peak transmission season.
Who is eligible for the RSV vaccine?
The updated eligibility criteria include adults aged 65 to 74 who have specific underlying health conditions. According to the UK Health Security Agency (UKHSA), individuals with chronic respiratory diseases—such as chronic obstructive pulmonary disease (COPD), asthma, or emphysema—are prioritized due to their heightened vulnerability to respiratory complications. Additionally, the program covers those with weakened immune systems, including patients undergoing immunosuppressive therapy or those with conditions that impair immune function.
This rollout is an extension of the existing program, which already provides the vaccine to those turning 75 and to pregnant women at 28 weeks gestation or beyond. The goal is to build a protective shield around the most vulnerable segments of the population. Patients who believe they meet the criteria are encouraged to check their eligibility through their primary care provider or via the official NHS vaccination portal.
Why the expansion matters for public health
The decision to include the 65–74 age bracket with specific health conditions reflects a proactive approach to managing seasonal viral surges. RSV, alongside influenza and COVID-19, represents a significant burden on the National Health Service during the winter. Clinical data suggests that vaccination significantly reduces the risk of severe disease in older cohorts, which in turn helps maintain hospital capacity for other emergency care services.
As a physician, I have observed that the primary challenge with RSV in older adults is the rapid progression from mild symptoms to severe pulmonary involvement. By shifting the focus to preventative immunization, the health service is working to mitigate the necessity for acute inpatient care. The vaccine’s effectiveness in this group is supported by data from the Joint Committee on Vaccination and Immunisation (JCVI), which recommended the program to protect those most likely to experience severe outcomes.
Practical steps for patients
For those eligible under the new September rollout, the process of receiving the vaccine is streamlined through standard NHS channels. Patients will typically be contacted by their GP practice; however, those who do not receive an invitation and believe they qualify should contact their surgery to confirm their status. It is important to note that the vaccine is administered as a single dose, which provides protection against the primary strains of the virus.
Clinicians are currently preparing for the September launch, ensuring that stocks are available across local primary care networks. As with all national immunization programs, the service remains free at the point of delivery. For the latest updates, residents can monitor their local Integrated Care Board (ICB) communications or visit the NHS website for real-time information regarding availability in their specific region.
The NHS is expected to provide further operational updates as the September launch date approaches. We encourage all readers to consult with their healthcare provider regarding their individual health profile and to stay informed through official government channels. Please share this information with those in your community who may be eligible to ensure they are prepared for the upcoming winter season.